Boston Scientific (BSX) Common Equity (2009 - 2026)

Boston Scientific has disclosed Common Equity across 18 years of filings, most recently posting $26.1 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $26.1 billion, up 16.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.1 billion (up 16.3% YoY), and the FY2025 annual result was $24.5 billion, up 12.41% from the prior year.
• Common Equity came in at $26.1 billion for Q1 2026 at Boston Scientific, up from $24.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $26.1 billion in Q1 2026 to a low of -$2.3 billion in Q1 2023.
• The 5-year median for Common Equity is $19.5 billion (2023), against an average of $13.8 billion.
• Across the five-year window, Common Equity plunged 103.09% in 2024 and soared 265475.0% in 2025, its largest moves.
• Boston Scientific's Common Equity stood at $269.0 million in 2022, then jumped by 7160.22% to $19.5 billion in 2023, then grew by 11.47% to $21.8 billion in 2024, then grew by 12.41% to $24.5 billion in 2025, then gained by 6.67% to $26.1 billion in 2026.
• The last three Common Equity figures came in at $26.1 billion (Q1 2026), $24.5 billion (Q4 2025), and $23.6 billion (Q3 2025), per Business Quant data.